Sweden
· Delayed Price · Currency is SEK Cantargia AB Company Description
Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases.
The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis.
It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Patheon Biologics B.V.
and BioWa Inc. for the manufacture and production of CAN04; and GEICAM, Spanish breast cancer group.
Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
| Country | Sweden |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Goran Forsberg |
Contact Details
Address: Ideon Gateway Lund, 223 63 | |
| Phone | 46 4 62 75 62 60 |
| Website | cantargia.com |
Stock Details
| Ticker Symbol | CANTA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0006371126 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Goran Forsberg | Chief Executive Officer |
| Thoas Fioretos M.D., Ph.D. | Founder and Scientific Advisor |
| Marcus Järås | Founder and Scientific Advisor |
| Kjell Sjöström | Founder |
| Patrik Renblad | Chief Financial Officer |
| Liselotte Larsson | Chief Operating Officer |
| Dr. David Liberg | Chief Scientific Officer |
| Nina Valkama | Executive Assistant of Administration and Finance |
| Dr. Dominique Tersago | Chief Medical Officer |
| Johanna Christensen | Financial Controller |